Targeted therapies, including tyrosine kinase inhibitors (e.g., vascular endothelial growth factor receptors or VEGFR inhibitors), immune checkpoint inhibitors, and novel agents targeting Notch signaling, are being investigated for metastatic disease [18]. Tyrosine kinase inhibitors (TKIs) targeting VEGFRs and other pathways have shown potential in slowing tumor progression in ACC. Here, KDR is linked to adrenal cortex carcinoma.